Top

Published in:

Open Access 01-12-2013 | Gastrointestinal Oncology

Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol

Authors: Anke M. J. Kuijpers, MD, Boj Mirck, MD, Arend G. J. Aalbers, MD, Simon W. Nienhuijs, MD, PhD, Ignace H. J. T. de Hingh, MD, PhD, Martinus J. Wiezer, MD, PhD, Bert van Ramshorst, MD, PhD, Robert J. van Ginkel, MD, PhD, Klaas Havenga, MD, PhD, Andreas J. Bremers, MD, PhD, Johannes H. W. de Wilt, MD, PhD, Elisabeth A. te Velde, MD, PhD, Vic J. Verwaal, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2013

Abstract

Purpose

This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin in the Netherlands following a national protocol.

Methods

In a multi-institutional study prospective databases of patients with peritoneal carcinomatosis (PC) from colorectal cancer and pseudomyxoma peritonei (PMP) treated according to the Dutch HIPEC protocol, a uniform approach for the CRS and HIPEC treatment, were reviewed. Primary end point was overall survival and secondary end points were surgical outcome and progression-free survival.

Results

Nine-hundred sixty patients were included; 660 patients (69 %) were affected by PC of colorectal carcinoma and the remaining suffered from PMP (31 %). In 767 procedures (80 %), macroscopic complete cytoreduction was achieved. Three-hundred and thirty one patients had grade III–V complications (34 %). Thirty-two patients died perioperatively (3 %). Median length of hospital stay was 16 days (range 0–166 days). Median follow-up period was 41 months (95 % confidence interval (CI), 36–46 months). Median progression-free survival was 15 months (95 % CI 13–17 months) for CRC patients and 53 months (95 % CI 40–66 months) for PMP patients. Overall median survival was 33 (95 % CI 28–38 months) months for CRC patients and 130 months (95 % CI 98–162 months) for PMP patients. Three- and five-year survival rates were 46 and 31 % respectively in case of CRC patients and 77 and 65 % respectively in case of PMP patients.

Conclusions

The results underline the safety and efficacy of cytoreduction and HIPEC for PC from CRC and PMP. It is assumed the uniform Dutch HIPEC protocol was beneficial.

Verwaal VJ, Van Ruth S, De Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.PubMedCrossRef

Integral Cancer Center the Netherlands (2011). The Netherlands Cancer Registration. http://www.cijfersoverkanker.nl. Accessed 12 Dec 2012.

Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699–705.PubMedCrossRef

Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, De Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717–25.PubMedCrossRef

Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63.PubMedCrossRef

Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–7.PubMedCrossRef

Bloemendaal ALA, Verwaal VJ, Van Ruth S, Boot H, Zoetmulder FAN. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol. 2005;31(10):1145–51.PubMedCrossRef

Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263–7.PubMedCrossRef

Klaver YLB, Simkens LHJ, Lemmens VEPP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7):617–23.PubMedCrossRef

10.

Sugarbaker PH, Schellinx MET, Chang D, Koslowe P, Meyerfeldt M von. Peritoneal Carcinomatosis from Adenocarcinoma of the Colon. World J Surg. 1996;20(5):585–92.PubMedCrossRef

11.

Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14(1):128–33.PubMed

12.

Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5.PubMedCrossRef

13.

Verwaal VJ, Ruth S Van, Witkamp A, Boot H, Slooten G Van, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg. 2005;12(1):9–12.CrossRef

14.

Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608–18.PubMedCrossRef

15.

Chua TC, Liauw J, Zhao J, Morris DL. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol. 2012;18(3):439–46.PubMedCrossRef

16.

Klaver YLB, Hendriks T, Lomme RMLM, Rutten HJT, Bleichrodt RP, De Hingh IHJT. Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study. Ann Surg Oncol. 2012;19(Suppl 3):S475–82.PubMedCrossRef

17.

Witkamp A, Bree E De. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001;27(6):365–74.PubMedCrossRef

18.

Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol. 1995;19(12):1390–408.PubMedCrossRef

19.

Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumours Pathology and Genetics of the digestive system. IARC Press: Lyon 2000.

20.

Verwaal VJ, Van Tinteren H, Van Ruth S, Zoetmulder F. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91(6):739–46.PubMedCrossRef

21.

Younan R, Kusamura S, Baratti D, Cloutier A-S, Deraco M. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):253–7.PubMedCrossRef

22.

Ryan BDP. Cytoreductive surgery and hyperthermic intraperitonal chemotherapy: history repeating itself or a new standard? American Society of Clinical Oncology 2011:127–128.23.24.

23.

Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251(5):896–901.PubMedCrossRef

24.

Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef

25.

Glockzin G, Rochon J, Arnold D, et al. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. COMBATAC study protocol. BMC Cancer. 2013;13(1):67.PubMedCrossRef

Title: Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol
Authors: Anke M. J. Kuijpers, MD
Boj Mirck, MD
Arend G. J. Aalbers, MD
Simon W. Nienhuijs, MD, PhD
Ignace H. J. T. de Hingh, MD, PhD
Martinus J. Wiezer, MD, PhD
Bert van Ramshorst, MD, PhD
Robert J. van Ginkel, MD, PhD
Klaas Havenga, MD, PhD
Andreas J. Bremers, MD, PhD
Johannes H. W. de Wilt, MD, PhD
Elisabeth A. te Velde, MD, PhD
Vic J. Verwaal, MD, PhD
Publication date: 01-12-2013
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 13/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3145-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 13/2013

Perioperative Complications in the Cancer Patient: A Robust Prognostic Factor

Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma: Improvements Needed in Population-Based Registries

Radioactive Seed Localization Compared to Wire Localization in Breast-Conserving Surgery: Initial 6-Month Experience

Clinical Course of Breast Cancer Patients with Isolated Sternal and Full-Thickness Chest Wall Recurrences Treated With and Without Radical Surgery

Epitrochlear Lymph Node Dissection and Axillary Lymph Node Biopsy. An Unusual Clinical Presentation in a Patient with Forearm Melanoma

Multigland Disease and Slower Decline in Intraoperative PTH Characterize Mild Primary Hyperparathyroidism